Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Clindamycin and TMP-SMX in Infants and Children
NCT02475876Phase 1Completed
- Sponsor
- Michael Cohen-Wolkowiez
- Start
- Nov 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clindamycin and trimethoprim + sulfamethoxazole in bacterial infection (2 arms), sponsored by Michael Cohen-Wolkowiez. Primary endpoints: Maximum observed plasma concentration at steady state - Clindamycin at 3 days, Area under the plasma concentration versus time curve at steady state - Clindamycin at 3 days and 2 more. Started Nov 2015; status: completed.
02
Drugs
clindamycintrimethoprim + sulfamethoxazole
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02475876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475876.